ADRB3 and melanoma: In regard to the immune regulation, pharmacological and molecular approaches with β-blockers (propranolol and SR59230A) and specific siRNA targeting of β2- or β3-ARs injected in B16-F10 melanoma-bearing mice, suggested an involvement of β3-AR subtype in the regulation of the immune-tolerance in melanoma microenvironment [90].